
CLAIMS

What is claimed is:

1. Use of a compound having the formula



, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating colon carcinoma or a pharmaceutically acceptable salt thereof,
wherein said medicament is to be administered in combination with a PD-1 signaling inhibitor.

2. The use of claim 1, wherein the PD-1 signaling inhibitor is an inhibitor of one or more of PD-1, PD-L1, and PD-L2.


3. The use of claim 2, wherein the PD-1 signaling inhibitor inhibits PD-1 or PD-L1.

4. The use of claim 3, wherein the PD-1 signaling inhibitor is pembrolizumab, nivolumab, atelolizumab, avelumab, durvalumab or pidilizumab.

5. The use of claim 4, wherein the PD-1 signaling inhibitor is pembrolizumab or nivolumab.

6. A pharmaceutical composition for use in treating colon carcinoma, comprising:

(a) a compound of the formula



or a pharmaceutically acceptable salt thereof;

(b) a PD-1 signaling inhibitor; and

(c) a pharmaceutically acceptable carrier or excipient.

7. The pharmaceutical composition of claim 6, wherein the PD-1 signaling inhibitor is an inhibitor of one or more of PD-1, PD-L1, and PD-L2.

8. The pharmaceutical composition of claim 6, wherein the PD-1 signaling inhibitor is pembrolizumab, nivolumab, atelolizumab, avelumab, durvalumab or pidilizumab.

9. The pharmaceutical composition of any one of claims 6 to 8, in the form of a tablet or capsule.